Aurinia Pharmaceuticals Inc.
US ˙ NasdaqGM ˙ CA05156V1022

SecurityAUPH / Aurinia Pharmaceuticals Inc.
InstitutionKnott David M
Latest Disclosed Ownership62,896 shares
Latest Disclosed Value $ 1,392,000
Knott David M reports 61.84% decrease in ownership of AUPH / Aurinia Pharmaceuticals Inc.

On November 12, 2021 - Knott David M filed a 13F-HR form disclosing ownership of 62,896 shares of Aurinia Pharmaceuticals Inc. (US:AUPH) valued at $1,391,888 USD as of September 30, 2021. The entity filed a previous 13F-HR on August 13, 2021 disclosing 164,840 shares of Aurinia Pharmaceuticals Inc.. This represents a change in shares of -61.84% during the quarter. The current value of the position is $996,273 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2021-11-12 2021-09-30 13F Aurinia Pharmaceuticals Common 05156V102 62,896 -101,944 -61.84 1,392 -34.83 0.5058
2021-08-13 2021-06-30 13F Aurinia Pharmaceuticals Common 05156V102 164,840 10,000 6.46 2,136 6.22 0.7592
2021-05-13 2021-03-31 13F Aurinia Pharmaceuticals Common 05156V102 154,840 -22,700 -12.79 2,011 -18.09 0.8603
2021-02-12 2020-12-31 13F Aurinia Pharmaceuticals Common 05156V102 177,540 42,940 31.90 2,455 23.80 1.1110
2020-11-13 2020-09-30 13F Aurinia Pharmaceuticals Common 05156V102 134,600 19,790 17.24 1,983 6.27 1.1635
2020-08-12 2020-06-30 13F Aurinia Pharmaceuticals Common 05156V102 114,810 107,510 1,472.74 1,866 1,660.38 1.0186
2020-05-13 2020-03-31 13F Aurinia Pharmaceuticals Common 05156V102 7,300 7,300 106 0.0669
2020-02-14 2019-12-31 13F Aurinia Pharmaceuticals Common 05156V102 0 -53,000 -100.00 0 -100.00
2019-11-12 2019-09-30 13F Aurinia Pharmaceuticals Common 05156V102 53,000 -5,000 -8.62 283 -25.92 0.1189
2019-08-12 2019-06-30 13F Aurinia Pharmaceuticals Common 05156V102 58,000 5,300 10.06 382 11.37 0.1611
2019-05-13 2019-03-31 13F Aurinia Pharmaceuticals Common 05156V102 52,700 52,700 343 0.1367
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.